G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation

Bone Marrow Transplantation

Volumn 48, Issue 3, 2013, Pages 357-362

  Abbi, K K S ^a   Zhu, J ^a   Ehmann, W C ^a   Epner, E ^a   Carraher, M ^a   Mierski, J ^a   Talamo, G ^a   Lucas, K ^a   Rybka, W ^a   Claxton, D ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

DLI; GVHD; HSCT

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84875210272     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.144     Document Type: Article

References (38)

1. Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Kapoor N et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838-843.
2. Frassoni F, Barrett AJ, Graniena A, Ernst P, Garthon G, Kolb HJ et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988; 70: 317-320.
3. Schmid C, Labopin M, Nagler A, Bornhäuser M, Fnke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allo-geneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938-4945.
4. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50-57.
5. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
6. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
7. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
8. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
9. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
10. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002; 30: 495-501.
11. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
12. Collins Jr. RH, Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992; 10: 391-395.
13. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
14. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
15. Kiss JE, Rybka WB, Winkelstein A, de Magalhaes-Silverman M, Lister J, D'Andrea P et al. Relationship of CD34 + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303-310.
16. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
17. Collins RHJ, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
18. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
19. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
20. Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E, Bär B, Preijers F, Van Der Maazen R et al. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk Lymphoma 1999; 32: 317-325.
21. Dazzi F, Szydlo RM, Apperley JF, Goldman JM. Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood 2002; 100: 2673-2674.
22. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414-421.
23. Fozza C, Szydlo RM, Abdel-Rehim MM, Nadal E, Goldman JM, Apperley JF et al. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol 2007; 136: 833-836.
24. Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998; 22: 1057-1063.
25. Lokhorst HM, Schattenberg A, Cornelissen JJ, Van Oers MH, Fibbe W, Russell L et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031-3037.
26. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89: 1517-1524.
27. Chen SH, Li X, Huang XJ. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004; 79: 178-184.
28. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.
29. Pan L, Delmonte Jr. J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
30. Zeng D, Jbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.
31. Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 allor-eactive CD4 + and CD8 + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585-593.
32. Krenger W, Cooke KR, Crawford JM, Sonis ST, Simmons R, Pan L et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 1996; 62: 1278-1285.
33. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540-3549.
34. Imami N, Brookes PA, Lombardi G, Hakooz B, Johns M, Goldman JM et al. Association between interleukin-4-producing T lymphocyte frequencies and reduced risk of graft-versus-host disease. Transplantation 1998; 65: 979-988.
35. Pan L, Teshima T, Hill GR, Bungard D, Brinson YS, Reddy VS et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood 1999; 93: 4071-4078.
36. Reyes E, Garcia-Castro L, Esquivel F, Hornedo J, Cortes-Funes H, Solovera J et al. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Br J Cancer 1999; 80: 229-235.
37. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998; 92: 215-222.
38. Eckardt JR, Roodman GD, Boldt DH, Clark GM, Alvarez R, Page C et al. Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transplant 1993; 11: 125-131.